Summary for Belumosudil

  • Trade Name: Rezurock (Kadmon)
  • Indications: Chronic graft-versus-host disease. (A complication of allogenuc hematopoietic stem cell transplantation).
  • Synonym: Belumosudil mesylate
  • Class: Kinase inhibitor
  • Half-life: 19 hours
  • FDA Approval Date: 07/16/2021
  • Clinically important, potentially hazardous interactions with:
    CYP3A Inducers, Proton pump inhibitors
  • Pregnancy: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top